Document:

<PAGE>
                                                                   EXHIBIT 10.31

                              CONSULTING AGREEMENT

         This Consulting Agreement (the "Agreement") is entered into effective
as of December 4, 2002, between Radiologix, Inc., a Delaware corporation
("Radiologix"), and Mark L. Wagar ("Wagar"), an individual residing in the State
of Texas.

                                    RECITALS

     Wagar has served as the Chairman of the Board and Chief Executive Officer
of Radiologix. Because Wagar's employment with Radiologix has ended, Radiologix
wishes to engage Wagar to serve as a consultant to Radiologix, upon and subject
to the terms and conditions set forth in this Agreement.

                                    AGREEMENT

     NOW, THEREFORE, in consideration of the premises and mutual covenants and
agreements set forth herein, and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties agree as
follows:

          1. ENGAGEMENT. Radiologix hereby appoints and engages Wagar as
     consultant effective as of the date of this Agreement with respect to the
     matters specified herein, subject to the terms and conditions of, and for
     the compensation provided in, this Agreement. Wagar accepts this
     appointment and engagement effective as of the commencement of the Term
     (defined below) as a consultant to Radiologix, subject to the terms and
     conditions of this Agreement.

          2. TASKS AND RESPONSIBILITIES OF PARTIES. During the Term (defined
     below) of this Agreement, Wagar will be subject to the direction of the
     Chairman of the Board of Radiologix. In addition, during the Term,
     Radiologix promises to furnish to Wagar Confidential Information of
     Radiologix, in order to permit Wagar to perform his obligations as set
     forth in this Agreement and on Exhibit A attached hereto.

          3. STANDARDS OF DUTY. During the Term, Wagar shall devote his best
     efforts and skills to his duties under this Agreement, endeavoring to
     utilize his full ability and knowledge of Radiologix's business and
     projecting a positive and professional image on behalf of Radiologix.

          4. NON-DISCLOSURE. Wagar acknowledges, understands and agrees that all
     Confidential Information (defined below), whether developed by Radiologix
     or others or whether developed by Wagar while carrying out the terms and
     provisions of this Agreement (or previously while employed by Radiologix),
     shall be the exclusive and confidential property of Radiologix and shall be
     regarded, treated and protected as such. Wagar shall not use, copy or
     transfer Confidential Information other than as is necessary in carrying
     out his duties pursuant to this Agreement or in preserving, defending or
     pursuing his rights or remedies under this Agreement or any other agreement
     or relationship between Wagar and Radiologix or its Affiliates.

          5. INVENTIONS AND DISCOVERIES. Any and all inventions, products,
     discoveries, improvements, copyrightable work, trademarks, service marks,
     ideas, processes, formulas, methods, designs, techniques or trade secrets
     made, developed, conceived or resulting from work performed by Wagar during
     the Term that may be directly or indirectly useful or related to the
     business of Radiologix shall be deemed Confidential Information for
     purposes of this Agreement and shall be Radiologix's exclusive property.
     Wagar shall also make available to Radiologix any and all information of
     which he had knowledge and that is relevant to the business of Radiologix
     and its Affiliates and shall make all suggestions and recommendations that
     he feels will benefit Radiologix.

          6. PROHIBITED ACTIVITIES.

             6.1.  DESCRIPTION OF PROSCRIBED ACTIONS. In consideration for the
                   disclosure of Confidential Information described in Section 3
                   of this Agreement, during the Term of this Agreement, Wagar
                   shall not:

                   (a) directly or indirectly, engage or invest in, own, manage,
                       operate, control or participate in the ownership,
                       management, operation or control of, be employed by,
                       associated or in any manner connected with, or render
                       services or advice to, any Competing Business (defined
                       below); provided, however, that Wagar may invest in the
                       securities of any enterprise (but without otherwise
                       participating in the activities of such enterprise) if
                       such securities are listed on any national or regional
                       securities exchange or have been registered under Section
                       12(g) of the Securities Exchange Act of 1934;

<PAGE>
                   (b) directly or indirectly, either as principal, agent,
                       independent contractor, consultant, director, officer,
                       employee, employer, advisor (whether paid or unpaid),
                       stockholder, partner or in any other individual or
                       representative capacity whatsoever, either for his own
                       benefit or for the benefit of any other Person (defined
                       below) or entity, divert or take away any customers or
                       clients of Radiologix, such activities are associated
                       with or related to the business referred to in (a)(i)
                       above; or

                   (c) directly or indirectly, either as principal, agent,
                       independent contractor, consultant, director, officer,
                       employee, employer, advisor (whether paid or unpaid),
                       stockholder, partner or in any other individual or
                       representative capacity whatsoever, either for his own
                       benefit or for the benefit of any other Person or entity,
                       either (i) hire, attempt to hire, contact or solicit with
                       respect to hiring, any employee of Radiologix, (ii)
                       induce or otherwise counsel, advise or encourage any
                       employee of Radiologix to leave the employment of
                       Radiologix, or (iii) induce any representative or agent
                       of Radiologix to terminate or modify its relationship
                       with Radiologix.

             6.2.  JUDICIAL MODIFICATION. Wagar agrees that if a court of
                   competent jurisdiction determines that the length of time or
                   any other restriction, or portion thereof, set forth in this
                   Section 6 is overly restrictive and unenforceable, the court
                   may reduce or modify such restrictions to those which it
                   deems reasonable and enforceable under the circumstances, and
                   as so reduced or modified, the parties hereto agree that the
                   restrictions of this Section 6 shall remain in full force and
                   effect. Wagar further agrees that if a court of competent
                   jurisdiction determines that any provision of this Section 6
                   is invalid or against public policy, the remaining provisions
                   of this Section 6 and the remainder of this Agreement shall
                   not be affected thereby, and shall remain in full force and
                   effect.

             6.3.  SURVIVAL OF COVENANTS. The covenants and agreements of Wagar
                   set forth in this Section 6 are of a continuing nature and
                   shall survive the expiration, termination or cancellation of
                   this Agreement regardless of the reason therefor.

     7. TERMINATION UPON DEATH. Notwithstanding any other provision of this
Agreement, at any time during the Term, Wagar's engagement hereunder shall
terminate upon his death; provided, however, that if Wagar shall die during the
Term, his heirs or estate (as the case may be) shall be entitled to retain all
payments previously made hereunder and no further payments shall be made
hereunder.

     8. INJUNCTIVE RELIEF. Because of the unique nature of the Confidential
Information, Wagar acknowledges, understands and agrees that Radiologix will
suffer immediate and irreparable harm if Wagar fails to comply with any of his
obligations under Sections 4, 5 and 6 of this Agreement, and that monetary
damages will be inadequate to compensate Radiologix for such breach.
Accordingly, Wagar agrees that Radiologix shall, in addition to any other
remedies available to it at law or in equity, be entitled to temporary,
preliminary, and permanent injunctive relief to enforce the terms of Sections 4,
5 and 6 without the necessity of proving inadequacy of legal remedies or
irreparable harm.

     9. COMPENSATION. Subject to the terms and conditions hereof, in
consideration of the consulting services to be rendered by Wagar to Radiologix
hereunder, and in consideration of the covenants of Wagar set forth in Sections
4, 5 and 6 herein, Radiologix hereby agrees to pay Wagar $18,416.67 per month
payable on the last day of each month

     10. TERM. This Agreement shall be for a term commencing on the earlier of
May 31, 2003 or the first date of employment of Radiologix's new Chief Executive
Officer (the "Separation Date") and ending on the earlier of six months after
the Separation Date or August 31, 2003 (the "Term"). If Wagar resigns his
positions with Radiologix prior to the Separation Date, accepts a full-time
position with another Person or entity prior to the Separation Date, or
otherwise breaches the Separation Agreement and Release dated December 4, 2002
between Wagar and Radiologix, this Agreement shall be null and void.

     11. REIMBURSEMENT OF EXPENSES. In the event Wagar is requested by
Radiologix to provide services which require travel, Radiologix will reimburse
Wagar for all such business expenses actually and reasonably incurred in
connection with the performance of the specific request. Radiologix will not be
required to reimburse Wagar for any expense which is not directly related to a
specific project which Radiologix has requested Wagar's assistance.

     12. INDEPENDENT CONTRACTOR. While serving as consultant, Wagar shall at all
times be an independent contractor rather than a co-venturer, agent, employee or
representative of Radiologix. Wagar is responsible for scheduling his own hours;
for determining where, when and how services are to be provided; and for
providing any and all equipment necessary to perform his duties within this
Agreement. Wagar acknowledges and agrees that he shall be obligated to report to
the Internal Revenue Service and all other taxing authorities all compensation
received by him under this Agreement. Wagar further acknowledges that he is

<PAGE>
responsible for making any and all payments for withholding for federal and
state unemployment taxes, social security and Medicare taxes, and any other
withholding payment required by the Internal Revenue Service or other taxing
authority.

          13. DEFINITIONS. The following terms shall have the meanings ascribed
     to them below, the following definitions to be equally applicable to both
     the singular and plural form of the terms:

              13.1. "Affiliate" shall mean when used with reference to a
                    specified Person: (i) any Person that directly or indirectly
                    through one or more intermediaries controls or is controlled
                    by or is under common control with the specified Person; and
                    (ii) any Person that is an officer of, partner in, or serves
                    in a similar capacity to, the specified Person or of which
                    the specified Person serves in a similar capacity; and (iii)
                    any Person owning or controlling ten percent (10%) or more
                    of the outstanding voting securities of such other entity;
                    and (iv) any member of the immediate family of the specified
                    Person or any legal representative or trustee for the
                    benefit of such member.

              13.2. "Competing Business" shall mean any individual, business,
                    firm, company, partnership, joint venture, organization, or
                    other entity that is involved in the acquisition or
                    management of radiology physician practices or that directly
                    provides management services in the area of radiology.

              13.3. "Confidential Information" shall have the meaning given it
                    in the Confidentiality, Proprietary Information and
                    Inventions Agreement Wagar executed in connection with
                    Wagar's Employment Agreement entered into between Wagar and
                    American Physician Partners, Inc. (now known as Radiologix)
                    on May 28, 1998, as amended on January 1, 1999, July 1,
                    2000, and February 11, 2002.

              13.4. "Person" shall mean an individual, partnership, corporation,
                    trust or other entity.

          14. GOVERNING LAW. This Agreement shall be deemed performable by all
     parties in, and venue shall be in the state or federal courts located in,
     Dallas County, Texas and the construction and enforcement of this Agreement
     shall be governed by Texas law without regard to its conflicts of law
     rules.

          15. ENTIRE AGREEMENT. This Agreement, which incorporates all prior
     understandings relating to its subject matter, contains the entire
     agreement of the parties with respect to its subject matter and shall not
     be modified except by written instrument executed by each party.

          16. SEVERABILITY. If any of the terms and conditions of this Agreement
     are held by any court of competent jurisdiction to contravene, or to be
     invalid under, the laws of any political body having jurisdiction over this
     subject matter, that contravention or invalidity shall not invalidate the
     entire Agreement. Instead, this Agreement shall be construed as it if did
     not contain the particular provision or provisions held to be invalid, the
     rights and obligations of the parties shall be construed and enforced
     accordingly, and this Agreement shall remain in full force and effect.

          17. CONSTRUCTION. The headings in this Agreement are inserted for
     convenience and identification only and are not intended to describe,
     interpret, define, or limit the scope, extent, or intent of this Agreement
     or any other provisions hereof. Whenever the context requires, the gender
     of all words used in this Agreement shall include the masculine, feminine,
     and neuter, and the number of all words shall include the singular and the
     plural. In the event of a conflict among this Agreement and any Exhibit,
     this Agreement shall control.

          18. COUNTERPARTS. This Agreement may be executed in any number of
     counterparts with the same effect as if all the parties had signed the same
     document. All counterparts shall be construed together and shall constitute
     one and the same instrument.

          19. SUCCESSORS AND ASSIGNS. Except as otherwise provided, this
     Agreement shall apply to, and shall be binding upon, the parties hereto,
     their respective successors and assigns, and all Persons claiming by,
     through or under any of these Persons. This Agreement is personal to Wagar
     and cannot be assigned or delegated by Wagar.

          20. NO THIRD PARTY BENEFICIARY. Any agreement to pay an amount or any
     assumption of liability herein contained, express or implied, shall be only
     for the benefit of the undersigned parties and their permitted successors
     and assigns, and such agreements and assumption shall not inure to the
     benefit of the obligees of any other party whomsoever, it being the
     intention of the undersigned that, except as otherwise expressly
     contemplated herein, no one shall be deemed to be a third party beneficiary
     of this Agreement.

     * * * * *

<PAGE>

     EXECUTED as of December 4, 2002.

                                        /s/ Mark L. Wagar
                                        ---------------------------------------
                                        Mark L. Wagar

                                        RADIOLOGIX, INC.

                                        By: /s/ Paul M. Jolas
                                            ------------------------------------
                                            Title: Exec. VP, General Counsel and
                                                   Secretary

<PAGE>
                                    EXHIBIT A
                           CONSULTING RESPONSIBILITIES

     Wagar shall use his best efforts to maintain Radiologix's business and
goodwill and reputation with the customers of Radiologix and Radiologix's
employees, suppliers, distributors, creditors and any others having business
relations with Radiologix and in the business community generally, during the
transition period. During the Term hereof, Wagar will be subject to the general
direction of Radiologix and will perform the consulting services requested by
Radiologix, at times and places as are mutually agreed upon by Wagar and
Radiologix; provided, however, that Wagar, subject to his other responsibilities
and long-standing commitments, shall be available for assignments, meetings, and
other projects during reasonable business hours with reasonable advance notice
from Radiologix. Wagar's duties shall include, but not be limited to, assisting
Radiologix in recruiting, screening, evaluating and recommending radiology
practices and imaging centers for affiliation with or acquisition by Radiologix.
In addition, Wagar shall assist Radiologix in its efforts to develop and expand
its (i) networks through the addition of hospitals and/or managed care
organizations, (ii) strategic alliances with other healthcare providers and
payors, (iii) relationships with equipment and supply vendors and (iv) plan for
outsourcing imaging services from hospitals.

     Wagar agrees to cooperate with Radiologix in any litigation or
administrative proceedings involving any matters which Wagar was involved during
his employment with Radiologix and the term of this Agreement. Radiologix shall
reimburse Wagar for travel expenses approved by Radiologix incurred in providing
such assistance.<PAGE>

                                                                   EXHIBIT 10.40

                              EMPLOYMENT AGREEMENT

This Employment Agreement ("Agreement") is entered into as of February 6, 2003,
between Radiologix, Inc., a Delaware corporation (the "Company"), and Stephen D.
Linehan ("Linehan").

In consideration of the mutual covenants and conditions set forth herein, the
parties hereby agree as follows:

1. EMPLOYMENT. The Company hereby employs Linehan in the capacity of Chief
Executive Officer. Linehan accepts such employment and agrees to perform such
services as are customary to such office and as shall from time to time be
assigned to him by the Board of Directors that are consistent with such office.
The Company and Linehan hereby acknowledge and agree that Linehan shall be
required to move to, and establish his primary residence in, the Dallas, Texas
area to perform the services contemplated by this Agreement.

2. TERM. The employment hereunder shall be for a period of three years,
commencing on February 6, 2003 (the "Commencement Date") and shall continue
until terminated as provided in Section 5. Linehan's employment will be on a
full-time basis requiring the devotion of such amount of his productive time as
is necessary for the efficient operation of the business of the Company;
provided, however, that Linehan may serve on the board of directors (or similar
entity) of one business organization, subject to prior written approval by the
Company's Board of Directors in its sole discretion.

3. COMPENSATION AND BENEFITS

3.1 SALARY. For the performance of Linehan's duties hereunder, the Company shall
pay Linehan an annual salary of $440,000, payable (less required withholdings)
no less frequently than twice monthly.

3.2 BONUS. The Board of Directors and Linehan will establish a mutually
acceptable bonus plan for 2003 that will provide, among other things, that he
will receive at least $264,000 if the Company achieves identified performance
goals based on the 2003 budget. Linehan will receive a bonus of at least
$125,000 for 2003 if he is employed by the Company on the one-year anniversary
of the Commencement Date. During the first employment year, the Board of
Directors and Linehan will establish a mutually acceptable bonus plan for the
second and subsequent employment years, which plan will provide Linehan with
appropriate incentives and the opportunity to earn bonus amounts comparable to
those available to top executives officers of similar companies.

3.3 STOCK OPTIONS. Upon commencement of Linehan's employment hereunder, the
Company shall grant to Linehan non-qualified options under the Company's Stock
Option Plan to purchase 900,000 shares of the Company's common stock at an
exercise price equal to the closing price of the Company's Common Stock on the
Commencement Date. Four hundred thousand of the options will vest as follows:

              200,000 on the Commencement Date;
              100,000 on the one-year anniversary of the Commencement Date; and
              100,000 on the two-year anniversary of the Commencement Date.

     The remainder of the options will vest as follows:

<PAGE>

<Table>
<Caption>
                               Closing Sales Price of the Company's Common Stock
                                           (Subject to Stock Splits)
        Number of Options              For 20 Consecutive Trading Days Is
        -----------------      -------------------------------------------------
        <S>                    <C>
             80,000                            greater than $5.00
             80,000                            greater than  7.50
             80,000                            greater than 10.00
             80,000                            greater than 12.50
             80,000                            greater than 15.00
            100,000                            greater than 17.50
</Table>

Upon the Company's consummation of a merger transaction or if any person or
entity completes a tender offer for not less than a majority of the shares of
the Company's common stock, the actual value received by holders of shares of
the Company's common stock in the merger, or by holders of shares of the
Company's common stock who tender and whose shares are purchased in the tender
offer, shall be used to determine whether Linehan shall be vested in the option
shares that vest based on the closing sales price of the Company's common stock,
without regard to the actual average closing sales prices of the Company's
common stock during the 20 consecutive trading day period prior to consummation
of such transaction.

Each option will be exercisable for a period of ten years from the Commencement
Date. Unvested options will immediately terminate upon termination of Linehan's
employment hereunder. Upon termination of his employment under Section 5.1(b),
5.1(d) or 5.1(e) after a Change of Control (as defined in Section 4), Linehan
will have 12 months to exercise vested options. Beginning with the third
anniversary of the Commencement Date, Linehan shall be considered for
participation in plans granting additional options or stock awards to top
executive personnel.

3.4 BENEFITS. Linehan shall be entitled to such medical, disability and life
insurance coverage and such vacation, sick leave and holiday benefits, if any,
and any other benefits as are made available to the Company's top executive
personnel, all in accordance with the Company's benefits program in effect from
time to time.

3.5 REIMBURSEMENT OF EXPENSES. Linehan shall be entitled to be reimbursed for
all reasonable expenses, including but not limited to expenses for travel, meals
and entertainment, incurred by Linehan in connection with and reasonably related
to the furtherance of the Company's business.

3.6 MOVING AND RELOCATION EXPENSES. The Company will reimburse Linehan for (i)
the reasonable, documented out-of-pocket costs incurred by Linehan in connection
with the relocation from his primary residence in Orlando, Florida ("Primary
Residence") to the Dallas, Texas area, including real estate commissions and
moving costs and (ii) his reasonable, documented attorneys' fees incurred in
connection with the execution of this Agreement; provided, however, that the
aggregate amount of such costs and fees that the Company shall be obligated to
reimburse shall not exceed $150,000; provided further, however, that Linehan
completes his move and establishes a primary residence in the Dallas, Texas,
area on or before September 1, 2003. The Company also shall pay to Linehan an
additional amount equal to any federal income tax liability that Linehan owes as
a result of the Company's reimbursement to Linehan of the relocation and moving
expenses and attorneys' fees described in this Section 3.6, to substantially the
effect that Linehan shall receive the benefit of the relocation and moving
expense and attorneys' fee reimbursement as if there were no federal income tax
liability for such reimbursement.

3.7 ANNUAL REVIEW. On each anniversary of the Commencement Date, the Board of
Directors will review Linehan's performance and compensation hereunder
(including salary, bonus and stock options and/or other equity incentives) and
in its sole discretion may increase such compensation in accordance with his
performance and then current labor market conditions.

4. CHANGE OF CONTROL. In the event of a Change of Control of the Company (as
defined below), all options then granted to Linehan which are unvested at the
date of the Change of Control will vest pursuant to the provisions of the
Company's 1996 stock option plan. In addition, in lieu of the provisions of
Section 5.2(b), if the Company terminates Linehan's employment hereunder at any
time following a Change of Control, then immediately upon such termination of
employment, the Company shall pay Linehan, in addition to the amounts required
under Section 5.2(a), a lump sum severance payment in an amount equal to the sum
of (i) the product of Linehan's then current annual salary for one year
multiplied by two plus (ii) the product of Linehan's most recent annual bonus
payment received for the fiscal year immediately preceding the Change of Control
multiplied by two. If the Company terminates Linehan's employment following a
Change of Control and prior to his receipt of a bonus for 2003, he will be
deemed to have received a bonus of $125,000 for purposes of clause (ii) above.

<PAGE>

In addition, the Company shall continue to provide Linehan with the benefits
described in Section 3.4 until the earlier of (i) the two-year anniversary of
the date of Linehan's termination of employment or (ii) the date on which
Linehan obtains substantially equivalent benefits from another party.

As used herein, a "Change of Control" of the Company shall be deemed to have
occurred:

     (a) Upon the consummation, in one transaction or a series of related
transactions, of the sale or other transfer of voting power (including voting
power exercisable on a contingent or deferred basis as well as immediately
exercisable voting power) representing effective control of the Company to a
person or group of related persons who, on the date of this Agreement, does not
have effective voting control of the Company, whether such sale or transfer
results from a tender offer or otherwise; or

     (b) Upon the consummation of a merger or consolidation in which the Company
is a constituent corporation and in which the Company's shareholders immediately
prior thereto will beneficially own, immediately thereafter, securities of the
Company or any surviving or new corporation resulting therefrom having less than
a majority of the voting power of the Company or any such surviving or new
corporation; or

     (c) Upon the consummation of a sale, lease, exchange or other transfer or
disposition by the Company of all or substantially all its assets to any person
or group of related persons:

5. TERMINATION

5.1 TERMINATION EVENTS. The employment hereunder will terminate upon the
occurrence of any of the following events:

     (a) Linehan dies;

     (b) the Company, by written notice to Linehan or his personal
representative, discharges Linehan due to the inability to perform the essential
duties assigned to him hereunder, with or without reasonable accommodation, for
a continuous period exceeding 120 days by reason of injury, physical or mental
illness or other disability, which condition has been certified by a physician;
provided, however, that prior to discharging Linehan due to such disability, the
Company shall give a written statement of findings to Linehan or his personal
representative setting forth specifically the nature of the disability and the
resulting performance failures, and Linehan shall have a period of ten days
thereafter to respond in writing to the Board of Directors' findings;

     (c) Linehan is discharged by the Board of Directors of the Company for
cause. As used in this Agreement, the term "cause" shall mean:

          (i) Linehan's conviction of (or pleading guilty or nolo contendere to)
     any (A) felony or (B) misdemeanor involving fraud, dishonesty in connection
     with the performance of his duties hereunder or moral turpitude; provided,
     however, that prior to discharging Linehan for cause, the Company shall
     give a written statement of findings to Linehan setting forth specifically
     the grounds on which cause is based, and Linehan shall have a period of ten
     days thereafter to respond in writing to the Board of Directors' findings;
     or

          (ii) the willful and continued failure of Linehan for a total of ten
     days within any fiscal year of the Company to substantially perform his
     duties with the Company (other than any such failure resulting from illness
     or disability) after a written demand for substantial performance is
     requested by the Company's Board of Directors, which specifically
     identifies the manner in which it is claimed Linehan has not substantially
     performed his duties, or (b) Linehan is willfully engaged in misconduct
     which has, or can reasonably be expected to have, a direct and material
     adverse monetary effect on the Company. For purposes of this Section no act
     or failure to act on Linehan's part shall be considered "willful" unless
     Linehan acted in bad faith or without a reasonable belief that Linehan's
     action or omission was in the best interest of the Company. No termination
     shall be effected for Cause unless Linehan has been provided with specific
     information as to the acts or omissions which form the basis of the
     allegation of Cause, and Linehan has had an opportunity to be heard, with
     counsel if he so desired, before the Board of Directors and such Board
     determines, by majority vote, in good faith that Linehan was guilty of
     conduct constituting "Cause" as herein defined, specifying the particulars
     thereof in detail;

     (d) Linehan is discharged by the Board of Directors of the Company without
cause, which the Company may do at any time, with at least 30 days advance
written notice;

     (e) Linehan voluntarily terminates his employment due to either (i) a
default by the Company in the performance of any of its obligations hereunder,
or (ii) an Adverse Change in Duties (as defined below), which default or Adverse
Change in Duties remains unremedied by the Company for a period of ten days
following its receipt of written notice thereof from Linehan; or

<PAGE>

     (f) Linehan voluntarily terminates his employment for any reason other than
the Company's default or an Adverse Change in Duties, which Linehan may do at
any time with at least 30 days advance notice.

As used herein, "Adverse Change in Duties" means an action or series of actions
taken by the Board of Directors of the Company, without Linehan's prior written
consent, which results in:

     (1) A change by the Board of Directors of the Company in Linehan's
reporting responsibilities, titles, job responsibilities or offices which
results in a material diminution of his status, control or authority as a chief
executive officer of a company that is (i) not controlled by a majority
stockholder, (ii) with annual revenues substantially equal to the Company's
revenues for its most recent fiscal year and (iii) whose common stock is
publicly traded; or

     (2) The assignment to Linehan of any positions, duties or responsibilities
which are materially inconsistent with Linehan's positions, duties and
responsibilities or status with the Company; or

     (3) A requirement by the Company that Linehan be based or perform his
duties anywhere other than (i) at the Company's corporate office location on the
date of this Agreement, or (ii) if the Company's corporate office location is
moved after the date of this Agreement, at a new location that is no more than
60 miles from such prior location; or

     (4) A failure by the Company to provide for Linehan's participation in any
current or future benefits or plans at a level or to an extent commensurate with
that of other top executives of the Company.

5.2 EFFECTS OF TERMINATION

     (a) Upon termination of Linehan's employment hereunder for any reason, the
Company will promptly pay Linehan all compensation owed to Linehan and unpaid
through the date of termination (including, without limitation, salary and
Linehan's expense reimbursements).

     (b) In addition, if Linehan's employment is terminated under Sections
5.1(b), (d) or (e), then the Company shall also pay Linehan, immediately upon
such termination of employment, a lump sum severance payment in an amount equal
to Linehan's then current annual salary.

     (c) The Company agrees that it will provide to Linehan confidential
information regarding the Company and its business. In consideration of, among
other things, the Company's obligation to disclose confidential information to
Linehan and his receipt of that confidential information, upon termination of
Linehan's employment hereunder for any reason, Linehan agrees that for the one
year period following the Termination Event:

          (i) Linehan will not directly or indirectly, whether as an individual,
     employee, director, consultant or advisor, or in any other capacity
     whatsoever, provide services to any person, firm, corporation or other
     business enterprise that (A) owns or operates diagnostic imaging centers or
     the provision of diagnostic imaging services, (B) provides administrative,
     management or other information services to radiology practices or (C)
     provides management services in the area of radiology, in each case unless
     he obtains the prior written consent of the Board of Directors.

          (ii) Linehan will not directly or indirectly encourage or solicit, or
     attempt to encourage or solicit, any individual to leave the Company's
     employ for any reason or interfere in any other manner with the employment
     relationships at the time existing between the Company and its current or
     prospective employees.

          (iii) Linehan will not induce or attempt to induce any provider,
     payor, customer, supplier, distributor, licensee or other business relation
     of the Company to cease doing business with the Company or in any way
     directly interfere with the existing business relationship between any such
     customer, supplier, distributor, licensee or other business relation and
     the Company.

Linehan acknowledges that monetary damages may not be sufficient to compensate
the Company for any economic loss which may be incurred by reason of breach of
the foregoing restrictive covenants. Accordingly, in the event of any such
breach, the Company shall, in addition to any remedies available to the Company
at law, be entitled to obtain equitable relief in the form of an injunction
precluding Linehan from continuing to engage in such breach.

If any restriction set forth in this paragraph is held to be unreasonable, then
Linehan and the Company agree, and hereby submit, to the reduction and
limitation of such prohibition to such area or period as shall be deemed
reasonable.

<PAGE>

6. GENERAL PROVISIONS

6.1 ASSIGNMENT. Neither party may assign or delegate any of his or its rights or
obligations under this Agreement without the prior written consent of the other
party.

6.2 ENTIRE AGREEMENT. This Agreement contains the entire agreement between the
parties with respect to the subject matter hereof and supersedes any and all
prior agreements between the parties relating to such subject matter.

6.3 MODIFICATIONS. This Agreement may be changed or modified only by an
agreement in writing signed by both parties hereto.

6.4 SUCCESSORS AND ASSIGNS. The provisions of this Agreement shall inure to the
benefit of, and be binding upon, the Company and its successors and permitted
assigns and Linehan and Linehan's legal representatives, heirs, legatees,
distributees, assigns and transferees by operation of law, whether or not any
such person shall have become a party to this Agreement and have agreed in
writing to join and be bound by the terms and conditions hereof.

6.5 GOVERNING LAW. This Agreement shall be governed by, and construed in
accordance with, the laws of the State of Texas.

6.6 SEVERABILITY. If any provision of this Agreement is held by a court of
competent jurisdiction to be invalid, void or unenforceable, the remaining
provisions shall nevertheless continue in full force and effect.

6.7 FURTHER ASSURANCES. The parties will execute such further instruments and
take such further actions as may be reasonably necessary to carry out the intent
of this Agreement.

6.8 NOTICES. Any notices or other communications required or permitted hereunder
shall be in writing and shall be deemed received by the recipient when delivered
personally or, if mailed, five days after the date of deposit in the United
States mail, certified or registered, postage prepaid and addressed, in the case
of the Company, to Radiologix, Inc., 3600 J.P. Morgan Chase Tower, 2200 Ross
Avenue, Dallas, Texas 75201-2776, attention: Board of Directors; and in the case
of Linehan, to the address shown for Linehan on the signature page hereof, or to
such other address as either party may later specify by at least ten days
advance written notice delivered to the other party in accordance herewith.

6.9 NO WAIVER. The failure of either party to enforce any provision of this
Agreement shall not be construed as a waiver of that provision, nor prevent that
party thereafter from enforcing that provision of any other provision of this
Agreement.

6.10 LEGAL FEES AND EXPENSES. In the event of any disputes under this Agreement,
each party shall be responsible for their own legal fees and expenses which it
may incur in resolving such dispute, unless otherwise prohibited by applicable
law or a court of competent jurisdiction.

6.11 COUNTERPARTS. This Agreement may be executed in counterparts, each of which
shall be deemed to be an original, but all of which together shall constitute
one and the same instrument.

[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

<PAGE>
IN WITNESS WHEREOF, the Company and Linehan have executed this Agreement,
effective as of the day and year first above written.

COMPANY                                          LINEHAN

RADIOLOGIX, INC.

By: /s/ Marvin S. Cadwell                        /s/ Stephen D. Linehan
    ---------------------------------            -------------------------------
Name:  Marvin S. Cadwell                         Stephen D. Linehan
Title: Chairman of the Board                     Address:
                                                         -----------------------

                                                         -----------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}]]